Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for William M. Vaughn, III.�
8.85
+0.26 (3.03%)
Real-time:   11:42AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.49 - 8.87
52 week 5.84 - 11.47
Open 8.59
Vol / Avg. 100,071.00/468,425.00
Mkt cap 379.85M
P/E     -
Div/yield     -
EPS -1.72
Shares 42.92M
Beta     -
Inst. own 93%
Nov 10, 2014
Q3 2014 Supernus Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 3, 2014
Supernus Pharmaceuticals Inc at FBR & Co Inaugural Healthcare Conference Add to calendar
Aug 12, 2014
Q2 2014 Supernus Pharmaceuticals Inc Earnings Call
Aug 11, 2014
Q2 2014 Supernus Pharmaceuticals Earnings Release
Jun 4, 2014
Supernus Pharmaceuticals at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 10.79% -767.73%
Operating margin 12.53% -594.64%
EBITD margin - -509.01%
Return on average assets 13.40% -90.03%
Return on average equity 41.18% -202.72%
Employees 235 -
CDP Score - -

Address

1550 East Gude Drive
ROCKVILLE, MD 20850
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.

Officers and directors

M. James Barrett Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 52
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 56
Bio & Compensation  - Reuters
Stefan K.F. Schwabe M.D., Ph.D. Executive Vice-President - Research & Development, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D., Senior Vice President- Intellectual Property, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales
Age: 55
Bio & Compensation  - Reuters
Jones W. Bryan Ph.D. Vice President - Business Development
Age: 49
Bio & Compensation  - Reuters
Frederick M. Hudson CPA., Independent Director
Age: 68
Bio & Compensation  - Reuters
Charles W. Newhall III Independent Director
Age: 69
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 61
Bio & Compensation  - Reuters